NYSE:BMYPharmaceuticals
Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab
Bristol Myers Squibb (NYSE:BMY) reported interim Phase 3 results for izalontamab brengitecan in advanced triple-negative breast cancer and esophageal squamous cell carcinoma.
The bispecific antibody-drug conjugate showed significant improvements in overall survival compared with standard chemotherapy in both trials.
The studies also reported meaningful gains in progression-free survival, pointing to a potential new standard of care in these hard-to-treat cancers.
Bristol Myers Squibb, a...